Prognostic implications of neuroendocrine differentiation and hormone production in patients with stage I nonsmall cell lung carcinoma

Cancer

Volumn 97, Issue 10, 2003, Pages 2487-2497

  Pelosi, Giuseppe ^a,c   Pasini, Felice ^b   Sonzogni, Angelica ^a   Maffini, Fausto ^a   Maisonneuve, Patrick ^c   Iannucci, Antonio ^d   Terzi, Alberto ^d   De Manzoni, Giovanni ^b   Bresaola, Enrica ^a   Viale, Giuseppe ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Chromogranin A; Hormone; Immunohistochemistry; Neuroendocrine differentiation; Nonsmall cell lung carcinoma; Survival; Synaptophysin

Indexed keywords

CHROMOGRANIN A; HORMONE; KI 67 ANTIGEN; SYNAPTOPHYSIN; CHROMOGRANIN; DIAGNOSTIC AGENT; NEDF PROTEIN, HUMAN; NERVE PROTEIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONFIDENCE INTERVAL; DISEASE COURSE; ENDOCRINE TUMOR; FEMALE; HAZARD ASSESSMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MULTIVARIATE ANALYSIS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY SYSTEM; STAINING; TUMOR CELL; ADENOCARCINOMA; CARCINOMA; CELL DIFFERENTIATION; DISEASE FREE SURVIVAL; ITALY; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SQUAMOUS CELL CARCINOMA; SURVIVAL;

ADENOCARCINOMA; AGED; CARCINOMA, NEUROENDOCRINE; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CHROMOGRANIN A; CHROMOGRANINS; DISEASE-FREE SURVIVAL; FEMALE; HORMONES; HUMANS; IMMUNOHISTOCHEMISTRY; ITALY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NERVE TISSUE PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS; SYNAPTOPHYSIN;

EID: 0038370938     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11376     Document Type: Article

References (68)

1. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Hystological typing of lung and pleural tumours. Berlin: Springer Verlag, 1999.
2. Corrin B. Pathology of the lungs. London: Churchill Livingstone, 2000:505-554.
3. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15:529-553.
4. Beasley MB, Thunnissen FB, Brambilla E, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol. 2000;31:1255-1265.
5. Axiotis CA. The neuroendocrine lung. In: Li Volsi V, Asa SL, editors. Endocrine pathology. New York: Churchill Livingstone, 2002:261-296.
6. Lyda MH, Weiss LM. Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. Hum Pathol. 2000;31:980-987.
7. Baldi A, Groger AM, Esposito V, Di Marino MP, Ferrara N, Baldi F. Neuroendocrine differentiation in non-small cell lung carcinomas. In Vivo. 2000;14:109-114.
8. Kiriakogiani-Psaropoulou P, Malamou-Mitsi V, Martinopoulou U, et al. The value of neuroendocrine markers in nonsmall cell lung cancer: a comparative immunohistopathologic study. Lung Cancer. 1994;11:353-364,
9. Senden N, Linnoila I, Timmer E, et al. Neuroendocrine-specific protein (NSP)-reticulons as independent markers for non-small cell lung cancer with neuroendocrine differentiation. An in vitro histochemical study. Histochem Cell Biol. 1997;108:155-165.
10. Gazdar AF, Helman LJ, Israel MA, et al. Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res. 1988;48: 4078-4082.
11. Lloyd RV, Douglas BR, Young WF. Endocrine diseases. Washington, DC: American Registry of Pathology and the Armed Forces Institute of Pathology, 2002:315.
12. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch. 1995;425:547-560.
13. Bepler G, Jaques G, Oie HK, Gazdar AF. Human chorionic gonadotropin and related glycoprotein hormones in lung cancer cell lines. Cancer Lett. 1991;58:145-150.
14. Dirnhofer S, Freund M, Rogatsch H, Krabichler S, Berger P. Selective expression of trophoblastic hormones by lung carcinoma: neuroendocrine tumors exclusively produce human chorionic gonadotropin alpha-subunit (hCGalpha). Hum Pathol. 2000;31:966-972.
15. Slodkowska J, Szturmowicz M, Rudzinski P, et al. Expression of CEA and trophoblastic cell markers by lung carcinoma in association with histological characteristics and serum marker levels. Eur J Cancer Prev. 1998;7:51-60.
16. Sheppard MN, Thurlow NP, Dewar A. Amphicrine differentiation in bronchioloalveolar cell carcinoma. Ultrastruct Pathol. 1994;18:437-441.
17. Kameya T, Yamaguchi K. The neuroendocrine lung. In: Kovacs K, Asa SL, editors. Functional endocrine pathology. Malden: Blackwell Science, 1998:513-528.
18. Carnaghi C, Rimassa L, Garassino I, Santoro A. Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer. Ann Oncol. 2001;12(Suppl 2):S119-S123.
19. Jacot W, Quantin X, Boher JM, et al. Brain metastases at the time of presentation of non-small cell lung cancer: a multicentric AERIO analysis of prognostic factors. Br J Cancer. 2001;84:903-909.
20. Pujol JL, Boher JM, Grenier J, Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer. 2001; 31:221-231.
21. Hiroshima K, Iyoda A, Shibuya K, et al. Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung. Ann Thorac Surg. 2002;73:1732-1735.
22. Iyoda A, Hiroshima K, Baba M, Saitoh Y, Ohwada H, Fujisawa T. Pulmonary large cell carcinomas with neuroendocrine features are high-grade neuroendocrine tumors. Ann Thorac Surg. 2002;73:1049-1054.
23. Petersen I. Rudolf-Virchow Prize 1999. Genetics of respiratory tract carcinomas: correlation of genotype and phenotype. Virchows Dtsch Ges Pathol. 1999;83:195-204.
24. Carles J, Rosell R, Ariza A, et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer. 1993;10:209-219.
25. Pujol JL, Simony J, Demoly P, et al. Neural cell adhesion molecule and prognosis of surgically resected lung cancer. Am Rev Respir Dis. 1993;148:1071-1075.
26. Kibbelaar RE, Moolenaar KE, Michalides RJ, et al. Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma. Eur J Cancer. 1991; 27:431-435.
27. Sundaresan V, Reeve JG, Stenning S, Stewart S, Bleehen NM. Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours. Br J Cancer. 1991;64:333-338.
28. Skov BG, Sorensen JB, Hirsch FR, Larsson LI, Hansen HH. Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. Ann Oncol. 1991;2:355-360.
29. Graziano SL, Mazid R, Newman N, et al. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. J Clin Oncol. 1989;7:1398-1406.
30. Berendsen HH, de Leij L, Poppema S, et al. Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol. 1989; 7:1614-1420.
31. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA. 2001;98:13790-13795.
32. Gajra A, Tatum AH, Newman N, et al. The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer. Lung Cancer. 2002;36:159-165.
33. Graziano SL, Tatum A, Herndon JE II, et al. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with Stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer. 2001;33:115-123.
34. Graziano SL, Kern JA, Herndon JE, et al. Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with Stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer. 1998;21:203-211.
35. Abbona G, Papotti M, Viberti L, Macri L, Stella A, Bussolati G. Chromogranin A gene expression in non-small cell lung carcinomas. J Pathol. 1998;186:151-156.
36. Hage R, Elbers HR, Brutel de la Riviere A, van den Bosch JM. Neural cell adhesion molecule expression: prognosis in 889 patients with resected non-small cell lung cancer. Chest. 1998;114:1316-1320.
37. Wertzel H, Grahmann PR, Bansbach S, Lange W, Hasse J, Bohm N. Results after surgery in undifferentiated large cell carcinoma of the lung: the role of neuroendocrine expression. Eur J Cardiothorac Surg 1997;12:698-702.
38. Schleusener JT, Tazelaar HD, Jung SH, et al. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Cancer. 1996;77:1284-1291.
39. Linnoila RI, Piantadosi S, Ruckdeschel JC. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. Chest. 1994;106(6 Suppl):367S-3671S.
40. Graziano SL, Tatum AH, Newman NB, et al. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected Stage I and II nonsmall cell lung cancer. Cancer Res. 1994;54:2908-2913.
41. Harada M, Yokose T, Yoshida J, Nishiwaki Y, Nagai K. Immunohistochemical neuroendocrine differentiation is an independent prognostic factor in surgically resected large cell carcinoma of the lung. Lung Cancer. 2002;38:177-184.
42. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA. 2001;98:13784-13789.
43. Shoji M, Dobashi Y, Morinaga S, Jiang SX, Kameya T. Tumor extension and cell proliferation in adenocarcinomas of the lung. Am J Pathol. 1999; 154:909-918.
44. D'Amico T, Massey M, Hemdon JE, Moore M-B, Harpole DH. A biological risk model for Stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg. 1999;117:736-743.
45. O'Neill AJ, Staunton MJ, Gaffney EF. Apoptosis occurs independently of bcl-2 and p53 over-expression in non-small cell lung carcinoma. Histopathology. 1996;29:45-50.
46. Takeshima Y, Yamasaki M, Nishisaka T, Kitaguchi S, Inai K. p21WAF1/CIP1 expression in primary lung adenocarcinomas: heterogeneous expression in tumor tissues and correlation with p53 expression and proliferative activities. Carcinogenesis. 1998;19:1755-1761.
47. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta. 1998; 1378:F21-F59.
48. Kerr KM. Pulmonary preinvasive neoplasia. J Clin Pathol. 2001;54:257-271.
49. Fong KM, Sekido Y, Minna JD. Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg. 1999;118:1136-1152.
50. Fontanini G, Boldrini L, Calcinai A, et al. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density. Clin Cancer Res. 1999;5:155-161.
51. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a perspective study. J Natl Cancer Inst. 1997;89:881-886.
52. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in Stage I lung cancer: relevance to prognosis. J Clin Oncol. 1997; 15:2858-2865.
53. Chandrachud LM, Pendetlon N, Chisholm DM, Horan MA, Schor AM. Relationship between vascularity, age and survival in non-small-cell lung cancer. Br J Cancer. 1997;76: 1367-1375.
54. Pelosi G, Pastorino U, Pasini F, et al. Independent prognostic value of fascin immunoreactivity in Stage I non-small cell lung cancer. Br J Cancer. 2003;88:537-547.
55. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934-944.
56. Travis WD, Gal AA, Colby TV, Klimstra DS, Falk R, Koss MN. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol. 1998;29:272-279.
57. Mountain CF. Revisions in the international system for staging for lung cancer. Chest. 1997;111:1710-1717.
58. Burry RW. Specificity controls for immunocytochemical methods. J Histochem Cytochem. 2000;48:163-166.
59. Pelosi G, Fraggetta F, Pasini F, et al. Immunoreactivity for thyroid transcription factor-1 in Stage I non-small cell lung carcinomas of the lung. Am J Surg Pathol. 2001;25:363-372.
60. Hu W, McCrea PD, Deavers M, Kavanagh JJ, Kudelka AP, Verschraegen CF. Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors. Clin Exp Metast. 2000;18:83-88.
61. Grothey A, Hashizume R, Sahin AA, McCrea PD. Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer. 2000;83:870-873.
62. Del Rosario A, Goncharuk VN, Tran TA, Sheehan CE, Ross JS. Fascin immunoreactivity correlates with tumor grade in non-small lung cancer (NSCLC) (abstract 1283). Mod Pathol. 2001;14:218A.
63. Tungekar MF, Gatter KC, Dunnill MS, Mason DY. Ki-67 immunostaining and survival in operable lung cancer. Histopathology. 1991;19:545-550.
64. Borges M, Linnoila RI, van de Velde HJ, et al. An achaetescute homologue essential for neuroendocrine differentiation in the lung. Nature. 1997;386:852-855.
65. Ball DW, Azzoli CG, Baylin SB, et al. Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. Proc Natl Acad Sci USA. 1993;90:5648-5652.
66. Loy TS, Darkow GV, Quesenberry JT. Immunostaining in the diagnosis of pulmonary neuroendocrine carcinomas. An immunohistochemical study with ultrastructural correlations. Am J Surg Pathol. 1995;19:173-182.
67. Kalina M, Grimelius L. Chromogranins or chromogranin-like proteins are present in lamellar bodies and pulmonary surfactant of rat alveolar type II cells. J Histochem Cytochem. 1991;39:213-220.
68. Goto K, Kodama T, Hojo F, et al. Clinicopathologic characteristics of patients with nonsmall cell lung carcinoma with elevated serum progastrin-releasing peptide levels. Cancer. 1998;82:1056-1061.